MARKET

LTRN

LTRN

Lantern Pharma Inc
NASDAQ
3.860
+0.190
+5.18%
After Hours: 3.860 0 0.00% 18:22 06/26 EDT
OPEN
3.630
PREV CLOSE
3.670
HIGH
3.925
LOW
3.602
VOLUME
147.15K
TURNOVER
--
52 WEEK HIGH
5.74
52 WEEK LOW
1.110
MARKET CAP
49.25M
P/E (TTM)
-2.6674
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at LTRN last week (0615-0619)?
Weekly Report · 5d ago
Weekly Report: what happened at LTRN last week (0608-0612)?
Weekly Report · 06/15 09:16
Lantern Pharma files to sell 2.24M shares of common stock for holders
TipRanks · 06/12 20:36
Lantern Pharma Announces Selling Stockholders May Sell Up To 2.24M Shares Of Common Stock
Benzinga · 06/12 20:34
LANTERN PHARMA - SELLING STOCKHOLDERS MAY SELL UP TO 2.24 MLN SHARES OF COMMON STOCK - SEC FILING
Reuters · 06/12 20:32
Weekly Report: what happened at LTRN last week (0601-0605)?
Weekly Report · 06/08 09:15
New to The Street Broadcasts Tonight on Bloomberg Television Across the United States, Latin America, and MENA at 6:30 PM ET
Barchart · 06/06 06:20
Lantern Pharma reports data, updates from Phase 2 Harmonic trial on LP-300
TipRanks · 06/02 13:02
More
About LTRN
Lantern Pharma Inc. is an artificial intelligence (AI) company. The Company is developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, leverages over 200 billion oncology-focused data points and a library of 200+ ML algorithms. It is engaged in the development of its pipeline of drug candidates that span multiple cancer indications, including both solid tumors and blood cancers and an antibody drug conjugate program. Its portfolio includes a Phase II clinical program (LP-300) in NSCLC focused on never-smokers and non-smokers with the EGFR exon 21 L858R mutation; planned Phase I b/II trials (LP-184) in precision, biomarker-defined solid tumors, and an ongoing Phase II program in hematologic malignancies and adult soft tissue sarcomas (LP-284). It is also focused on the clinical execution of its therapies for CNS and brain cancers through Starlight Therapeutics Inc.

Webull offers Lantern Pharma Inc stock information, including NASDAQ: LTRN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LTRN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LTRN stock methods without spending real money on the virtual paper trading platform.